Mechanical phenotype is important for stromal aromatase expression

Steroids

Volumn 76, Issue 8, 2011, Pages 797-801

  Ghosh, Sagar ^a   Kang, Tao ^a   Wang, Howard ^b   Hu, Yanfen ^a   Li, Rong ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Aromatase; Cell density; Cell shape; ECM; Mammographic density; Mechanical phenotype

Indexed keywords

AROMATASE; BETA1 INTEGRIN; CD31 ANTIGEN; CD45 ANTIGEN; CD61 ANTIGEN; CELL SURFACE MARKER; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; THY 1 ANTIGEN;

BREAST CANCER; CELL CULTURE; CELL DENSITY; CELL SHAPE; CONFERENCE PAPER; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN CELL; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL;

AROMATASE; BREAST; BREAST NEOPLASMS; CELL COUNT; CELL SHAPE; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MAMMOGRAPHY; MEMBRANE PROTEINS; PHENOTYPE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 79958765502     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2011.02.039     Document Type: Conference Paper

References (52)

1. Chen S, Zhou D, Yang C, Okubo T, Kinoshita Y, Yu B, et al. Modulation of aromatase expression in human breast tissue. J Steroid Biochem Mol Biol 2001;79:35-40. (Pubitemid 34158776)
2. Simpson ER, Misso M, Hewitt KN, Hill RA, Boon WC, Jones ME, et al. Estrogen-the good, the bad, and the unexpected. Endocr Rev 2005;26:330-2.
3. Simpson ER, Clyne C, Rubin G, Boo WC, Robertson K, Britt K, et al. Aromatase-a brief overview. Annu Rev Physiol 2002;64:93-127.
4. Sasano H, Harada N. Intratumoral aromatase in human breast, endometrial, and ovarian malignacies. Endocr Rev 1998;19:583-607.
5. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005;57:359-83. (Pubitemid 41196955)
6. Brodie A, Lu Q, Long B. Aromatase and its inhibitors. J Steroid Biochem Mol Biol 1999;69:205-10. (Pubitemid 29305538)
7. Morales L, Neven P, Paridaens R. Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting. Curr Opin Oncol 2005;17:559-65. (Pubitemid 41566408)
8. van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 1985;45:2900-6. (Pubitemid 15232767)
9. Meng L, Zhou J, Sasano H, Suzuki T, Zeitoun KM, Bulun SE. Tumor necrosis factor alpha and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein alpha and peroxisome proliferator-activated receptor gamma: mechanism of desmoplastic reaction. Cancer Res 2001;61:2250-5. (Pubitemid 32692055)
10. Richards SK, Parton LE, Leclerc I, Rutter GA, Smith RM. Over-expression of AMP-activated protein kinase impairs pancreatic β-cell function in vivo. J Endocrinol 2005;187:225-35. (Pubitemid 41685182)
11. Brueggemeier RW, Richards JA, Petrel TA. Aromatase and cyclooxygenases: enzymes in breast cancer. J Steroid Biochem Mol Biol 2003;86:501-7. (Pubitemid 37412590)
12. Zhou J, Suzuki T, Kovacic A, Saito R, Miki Y, Ishida T, et al. Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer. Cancer Res 2005;65:657-63.
13. Zhou J, Gurates B, Yang S, Sebastian S, Bulun SE. Malignant breast epithelial cells stimulate aromatase expression via promoter ii in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. Cancer Res 2001;61: 2328-34. (Pubitemid 32692067)
14. Quinn AL, Burak Jr WE, Brueggemeier RW. Effects of matrix components on aromatase activity in breast stromal cells in culture. J Steroid Biochem Mol Biol 1999;70:249-56. (Pubitemid 29528437)
15. Ghosh S, Choudary A, Ghosh S, Musi N, Hu Y, Li R. IKKβ mediates cell shape-induced aromatase expression and estrogen biosynthesis in adipose stromal cells. Mol Endocrinol 2009.
16. Mandava U, Kirma N, Tekmal RR. Aromatase overexpression transgenic mice model: cell type specific expression and use of letrozole to abrogate mammary hyperplasia without affecting normal physiology. Steroid Biochem Mol Biol 2001;79:27-34. (Pubitemid 34158775)
17. Keshava N, Mandava U, Kirma N, Tekmal RR. Acceleration of mammary neoplasia in aromatase transgenic mice by 7,12-dimethylbenz[a]anthracene. Cancer Lett 2001;167:125-33. (Pubitemid 32706674)
18. Boyd NF, Lockwood GA, Martin LJ, Knight JA, Byng JW, Yaffe MJ, et al. Mammographic densities and breast cancer risk. Breast Dis 1998;10:113-26. (Pubitemid 28470207)
19. Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res 2003;5:R129-35.
20. Li Z, Bowerman S, Heber D. Health ramifications of the obesity epidemic. Surg Clin North Am 2005;85:681-701. (Pubitemid 41095465)
21. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1159-69.
22. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356:227-36. (Pubitemid 46143226)
23. Vachon CM, van Gils CH, Sellers TA, Ghosh K, Pruthi S, Brandt KR, et al. Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res 2007;9:217.
24. Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995;87:670-5.
25. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1662-9.
26. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growth factor (IGF) I. IGF-binding protein 3, and mammographic density. Cancer Res 2000;60:3744-8.
27. Ursin G. Mammographic density as indicator of breast cancer risk. Tidsskr Nor Laegeforen 2003;123:3373-6. (Pubitemid 38281536)
28. Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 2004;230:29-41. (Pubitemid 37549780)
29. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 2005;6:798-808. (Pubitemid 41430721)
30. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, et al. Collagen density promotes mammary tumor initiation and progression. BMC Med 2008;6:11.
31. Provenzano PP, Inman DR, Eliceiri KW, Keely PJ. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage. Oncogene 2009;28:4326-43.
32. Guo YP, Martin LJ, Hanna W, Banerjee D, Miller N, Fishell E, et al. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 2001;10:243-8. (Pubitemid 34288536)
33. Diorio C, Pollak M, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, et al. Insulin-like growth factor-I. IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 2005;14:1065-73.
34. Bremnes Y, Ursin G, Bjurstam N, Rinaldi S, Kaaks R, Gram IT. Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women. Int J Cancer 2007;121:2506-11. (Pubitemid 350022421)
35. Vachon CM, Sasano H, Ghosh K, Brandt KR, Watson DA, Reynolds C, et al. Aromatase immunoreactivity is increased in mammographically dense regions of the breast. Breast Cancer Res Treat 2011;125(1):243-52.
36. Katz AJ, Tholpady A, Tholpady SS, Shang H, Ogle RC. Cell surface and transcriptional characterization of human adipose-derived adherent stromal (hADAS) cells. Stem Cells 2005;23:412-23. (Pubitemid 40404460)
37. Ghosh S, Lu Y, Katz A, Hu Y, Li R. Tumor Suppressor BRCA1 Inhibits a Breast Cancer-Associated Promoter of the Aromatase Gene (Cyp19) in Human Adipose Stromal Cells. Am J Physiol Endocrinol Metab 2007;292:246-52.
38. Hu Y-F, Ghosh S, Amleh A, Yue W, Lu Y, Katz A, et al. Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene 2005;24:8343-8. (Pubitemid 43256356)
39. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007;8:49-62. (Pubitemid 46012014)
40. Karin M. The IkappaB kinase-a bridge between inflammation and cancer. Cell Res 2008;18:334-42. (Pubitemid 351333897)
41. Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. Nat Rev Cancer 2009;9:108-22.
42. Gieni RS, Hendzel MJ. Mechanotransduction from the ECM to the genome: are the pieces now in place? J Cell Biochem 2008;104:1964-87.
43. Engler AJ, Griffin MA, Sen S, Bonnemann CG, Sweeney HL, Discher DE. Myotubes differentiate optimally on substrates with tissue-like stiffness: pathological implications for soft or stiff microenvironments. J Cell Biol 2004;166:877-87. (Pubitemid 39249838)
44. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell 2006;126:677-89. (Pubitemid 44233625)
45. McBeath R, Pirone DM, Nelson CM, Bhadriraju K, Chen CS. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev Cell 2004;6:483-95. (Pubitemid 38456178)
46. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005;8:241-54. (Pubitemid 41317594)
47. Chrzanowska-Wodnicka M, Burridge K. Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J Cell Biol 1996;133:1403-15. (Pubitemid 26192339)
48. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009;139:891-906.
49. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996;137:5739-42. (Pubitemid 26423150)
50. Richards JA, Brueggemeier RW. Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. J Clin Endocrinol Metab 2003;88:2810-6. (Pubitemid 36724460)
51. Mendelson CR, Corbin CJ, Smith ME, Smith J, Simpson ER. Growth factors suppress and phorbol esters potentiate the action of dibutyryl adenosine 3′,5′-monophosphate to stimulate aromatase activity of human adipose stromal cells. Endocrinology 1986;118:968-73. (Pubitemid 16080125)
52. Evans CT, Corbin CJ, Saunders CT, Merrill JC, Simpson ER, Mendelson CR. Regulation of estrogen biosynthesis in human adipose stromal cells. Effects of dibutyryl cyclic AMP, epidermal growth factor, and phorbol esters on the synthesis of aromatase cytochrome P-450. J Biol Chem 1987;262: 6914-20. (Pubitemid 17104151)